DermSafe Hand Sanitizer Provides Effective Alternative as Hand Dermatitis Increases from Excessive Use of Alcohol Sanitizers and Increased Hand Washing
- Unique polymers in DermSafe retain moisture to help protect against excessive dry hands & contact dermatitis
- Chlorhexidine Gluconate (CHG) used by doctors and dentists around the globe to kill germs
- Recipient of the Canadian Dermatology Review Panel (DRP) Seal of Approval
VANCOUVER, BC – December 16, 2020 (CSE: OVAT and OTC: OVATF) – Ovation Science Inc. (“Ovation” or the “Company”) discusses the use of its non-alcohol hand sanitizer DermSafe® as an effective option to combat hand dermatitis (excessive dry hands) which is now prevalent due to increased hand washing and use of alcohol hand sanitizers. In addition, Health Canada recently increased its recall list to over eighty alcohol-based hand sanitizers as they may pose health risks (Health Canada Recall and Safety Alerts, December 11, 2020). Ovation’s DermSafe is on Health Canada’s approved list of hand sanitizers that meet Health Canada’s requirements for sale in Canada (Refer to “Canada.ca: Hard-surface disinfectants and hand sanitizers (COVID-19): List of hand sanitizers authorized by Health Canada”).
Health Canada and the Centers for Disease Control and Prevention (CDC) have advised everyone to wash our hands frequently and/or use a hand sanitizer in order to help combat the spread of the coronavirus. This preventive measure, although critical, has for some people caused complications, especially for healthcare workers, restaurant personnel and others that constantly wash their hands. This can result in dry, cracked hands, even hand dermatitis due to a reduction in the skin’s natural skin barrier. Hand dermatitis can interfere with work and quality of life. In addition, not all alcohol hand sanitizer are effective or deemed safe. Since June 2020, more than eighty alcohol-based hand sanitizers have been recalled by Health Canada as they determined they presented a health risk to the population. The risks includes dermatitis, skin or eye irritation, even respiratory problems and headaches (Vancouver Sun, “COVID-19: Avoid these hand sanitizers that are recalled in Canada”; Sep 19, 2020).
“It’s winter and we all know how dry our hands can get just from the weather alone, never mind all of the hand washing and sanitizer use. DermSafe is an effective alternative to alcohol hand sanitizers as it is a non-drying lotion made with our patented polymer Invisicare® which acts like a protective glove on your hands. Additionally, we use chlorhexidine gluconate or CHG, which has been safely used in soaps to prevent the spread of germs around the world for over 60 years,” said Terry Howlett, CEO of Ovation Science. He added, “We keep hearing from customers that have tried DermSafe that they cannot believe how great their hands feel after using DermSafe. This is also verified by an independent study conducted by California Skin Research Institute, that shows how our Invisicare technology used in DermSafe, retains the moisture level in your hands; even with multiple hand washings.”
DermSafe is available online at Amazon.ca, and at Source For Sports independent retail stores across Canada and at SourceForSports.ca. Commercial orders can be placed through our distributors by contacting email@example.com.
For information about DermSafe and to order visit: https://dermsafe.com
For information about Ovation Science products visit: https://ovationscience.com/products/
Statements have not been evaluated by Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.
About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website ovationscience.com.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of approval or future sales in Canada, China or other countries or that there will be continued growth for either product lines. There are no guarantees of future performance. There is no assurance that cannabis product sales will continue to increase or that Ovation will find licensees outside of the USA. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
FOR INVESTOR RELATIONS:
Phone: 604-684-6730 or Toll Free at 866-684-6730
FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:
Phone: 604.283.0903 ext. 4